…
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Regencell Bioscience Holdings Ltd is a small-cap biotechnology company listed on NASDAQ; public disclosures about its specific programs and financials are limited or fragmented, so detailed product descriptions are not widely available. Its long-term growth may depend on clinical progress, regulatory approvals, strategic partnerships and successful commercialization of any therapeutic candidates, which could support upside for investors seeking early-stage biotech exposure.
The most important investment risks include early-stage clinical and regulatory uncertainty, limited public information and market liquidity, and the potential need for additional financing that could dilute existing shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -6.06M | -7.59M | -1.35M | -0.81M | -0.39M |
| Minority interest | 0.19M | 0.15M | - | - | - |
| Net income | -5.87M | -7.42M | -1.35M | -0.81M | -0.39M |
| Selling general administrative | 4.43M | 5.08M | 0.94M | 0.31M | 0.16M |
| Selling and marketing expenses | 0.26M | 0.03M | 0.00M | 0.11M | 0.00M |
| Reconciled depreciation | 0.77M | 0.60M | 0.03M | 0.01M | 0.00M |
| Ebit | -6.27M | -7.62M | -1.38M | -0.81M | -0.39M |
| Ebitda | -5.50M | -7.01M | -1.35M | -0.80M | -0.39M |
| Depreciation and amortization | 0.77M | 0.60M | 0.03M | 0.01M | - |
| Operating income | -6.27M | -7.62M | -1.38M | -0.81M | -0.39M |
| Other operating expenses | 6.27M | 7.62M | 1.38M | 0.81M | 0.39M |
| Interest expense | - | 0.02M | 0.00M | 0.00M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Income tax expense | -0.19M | -0.17M | -0.03M | - | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 6.27M | 7.62M | 1.38M | 0.81M | 0.39M |
| Total other income expense net | 0.21M | 0.02M | 0.03M | - | - |
| Net income from continuing ops | -6.06M | -7.59M | -1.35M | -0.81M | -0.39M |
| Net income applicable to common shares | - | -7.45M | -1.35M | -0.81M | -0.39M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 12.62M | 18.02M | 0.34M | 0.51M | 0.24M |
| Other current assets | - | 0.03M | 0.01M | - | - |
| Total liab | 0.63M | 0.94M | 4.34M | 3.16M | 2.08M |
| Total stockholder equity | 12.03M | 17.07M | -4.00M | -2.65M | -1.84M |
| Deferred long term liab | - | - | 0.17M | - | - |
| Other current liab | 0.17M | 0.17M | 0.66M | 0.10M | - |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -17.32M | -11.44M | -4.00M | -2.65M | -1.84M |
| Other assets | - | 0.11M | 0.19M | 0.02M | - |
| Cash | 1.56M | 6.42M | 0.06M | 0.39M | 0.24M |
| Total current liabilities | 0.61M | 0.58M | 4.34M | 3.16M | 2.08M |
| Net debt | -1.10M | -5.65M | 3.62M | 2.68M | 1.84M |
| Short term debt | 0.44M | 0.41M | 3.68M | 3.07M | 2.08M |
| Short long term debt | - | - | 3.68M | 3.07M | 2.08M |
| Short long term debt total | 0.46M | 0.77M | 3.68M | 3.07M | 2.08M |
| Other stockholder equity | 29.43M | 28.51M | 0.00M | 0.00M | 0.00M |
| Property plant equipment | - | 1.46M | 0.08M | 0.11M | - |
| Total current assets | 11.62M | 16.44M | 0.07M | 0.39M | 0.24M |
| Net tangible assets | - | 17.07M | -4.00M | -2.65M | -1.84M |
| Short term investments | 10.00M | 10.00M | - | - | - |
| Net receivables | 0.06M | 0.03M | 0.01M | - | - |
| Inventory | - | -0.03M | -0.01M | - | - |
| Accumulated other comprehensive income | -0.09M | - | - | -0.01M | - |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Non currrent assets other | 0.11M | 0.11M | 0.19M | 0.02M | - |
| Non current assets total | 1.00M | 1.57M | 0.27M | 0.13M | 0.00M |
| Capital lease obligations | 0.46M | 0.77M | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | 0.06M | -10.00M | -10.00M | -0.12M | -10.00M |
| Change to liabilities | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total cashflows from investing activities | - | -10.78M | -10.78M | -0.12M | -0.12M |
| Net borrowings | - | -0.43M | 0.61M | 0.99M | 0.48M |
| Total cash from financing activities | 0.13M | 22.41M | 0.44M | 0.99M | 0.48M |
| Change to operating activities | - | -1.02M | 0.55M | 0.08M | 0.08M |
| Net income | -6.06M | -7.59M | -1.35M | -0.81M | -0.39M |
| Change in cash | -4.85M | 6.36M | -0.33M | 0.14M | 0.09M |
| Begin period cash flow | 6.42M | 0.06M | 0.39M | 0.24M | 0.15M |
| End period cash flow | 1.56M | 6.42M | 0.06M | 0.39M | 0.24M |
| Total cash from operating activities | -4.96M | -5.27M | -0.77M | -0.73M | -0.39M |
| Issuance of capital stock | 0.00M | 22.67M | - | - | - |
| Depreciation | 0.77M | 0.60M | 0.03M | 0.01M | 0.01M |
| Other cashflows from financing activities | 0.13M | -0.27M | 0.44M | -0.12M | 0.48M |
| Change to netincome | - | 2.60M | 2.75M | 2.75M | 2.75M |
| Capital expenditures | 0.03M | 0.78M | 0.78M | 0.12M | 0.12M |
| Change in working capital | -0.51M | -1.02M | 0.55M | 0.08M | 0.00M |
| Stock based compensation | 0.92M | 2.76M | - | - | - |
| Other non cash items | -0.09M | -0.01M | - | - | - |
| Free cash flow | -4.99M | -6.05M | -0.77M | -0.84M | -0.39M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RGC Regencell Bioscience Holdings Ltd |
-0.18 4.13% |
4.18 | - | - | - | 4.12 | -6.99 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 23.11 |
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Chinachem Leighton Plaza, Causeway Bay, Hong Kong
852 2155 0823
12
| Name | Title | Year Born |
|---|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO | 1973 |
| Ms. Michelle Chan | Financial Controller | NA |
| Mr. Wai Hong Chung | COO & Chief Strategy Officer | 1977 |
| Dr. Yi-Chung Chao Ph.D. | Chief Medical Officer & Director | 1964 |
| Mr. Tien Hsiang Chau | Exec. Officer | 1970 |
| Dr. Yi-Chung Chao Ph.D. | Special Advisor & Director | 1964 |
| Mr. Tien Hsiang Chau | Executive Officer | 1970 |
| Ms. Antonia Assang | Senior Vice President of Project Management | NA |
| Mr. Yat-Pui Au | Chief Business Officer | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.